Your shopping cart is currently empty

GPR183 antagonist-2 (compound 32), a selective antagonist of GPR183, exhibits excellent water solubility and pharmacokinetic properties. This compound effectively diminishes paw and joint swelling, and reduces gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a dose-dependent manner within a collagen-induced arthritis (CIA) mouse model. GPR183 antagonist-2 is applicable in researching autoimmune diseases [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | GPR183 antagonist-2 (compound 32), a selective antagonist of GPR183, exhibits excellent water solubility and pharmacokinetic properties. This compound effectively diminishes paw and joint swelling, and reduces gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a dose-dependent manner within a collagen-induced arthritis (CIA) mouse model. GPR183 antagonist-2 is applicable in researching autoimmune diseases [1]. |
| Molecular Weight | 432.38 |
| Formula | C20H18F2N4O5 |
| Cas No. | 2924063-98-7 |
| Smiles | C(=C/C(=O)N1CCN(C(=O)C=2C=NC(OC)=NC2)CC1)\C=3C=C4C(=CC3)OC(F)(F)O4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.